

# A phase II trial of continuous-infusion 6-mercaptopurin

Cancer Chemotherapy and Pharmacology

26, 343-344

DOI: 10.1007/bf02897290

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytostatics and immunosuppressive drugs. Side Effects of Drugs Annual, 1992, 16, 512-528.	0.6	0
2	Cell-Kinetics and Biochemical Pharmacology of Methotrexate and 6-Mercaptopurine in Human Malignant T-Lymphoblasts. Klinische Padiatrie, 1992, 204, 293-298.	0.6	5
3	A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. Cancer Chemotherapy and Pharmacology, 1992, 30, 155-157.	2.3	5
4	The clinical pharmacology of 6-mercaptopurine. European Journal of Clinical Pharmacology, 1992, 43, 329-339.	1.9	578
5	6-Mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochemical Pharmacology, 1993, 45, 1455-1463.	4.4	88
6	Intravenous mercaptopurine: life begins at 40.. Journal of Clinical Oncology, 1993, 11, 1826-1831.	1.6	35
7	Advances in the treatment of meningeal cancers. Critical Reviews in Oncology/Hematology, 1995, 20, 87-98.	4.4	6
8	An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology, 1995, 109, 1808-1817.	1.3	153
9	Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 anti-neoplastic agents. Annals of Oncology, 1997, 8, 15-25.	1.2	34
10	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology, 1999, 117, 527-535.	1.3	236
11	Hepatotoxicity of Chemotherapy. Oncologist, 2001, 6, 162-176.	3.7	378
12	Hepatotoxicity of chemotherapy. Expert Opinion on Drug Safety, 2002, 1, 339-353.	2.4	3
13	Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Current Oncology Reports, 2003, 5, 29-40.	4.0	29
14	Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood, 2003, 101, 3809-3817.	1.4	332
15	Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia, 2005, 19, 721-726.	7.2	27
17	Current Treatment of Leptomeningeal Metastases: Systemic Chemotherapy, Intrathecal Chemotherapy and Symptom Management. , 2005, 125, 121-146.		14
18	Hepatotoxicity of Chemotherapy. Seminars in Oncology, 2006, 33, 50-67.	2.2	228
19	Thiopurines: Factors influencing toxicity and response. Biochemical Pharmacology, 2010, 79, 1211-1220.	4.4	52

#	ARTICLE	IF	CITATIONS
20	Chemotherapy-Induced Hepatotoxicity. Clinics in Liver Disease, 2013, 17, 671-686.	2.1	39
21	Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemotherapy and Pharmacology, 2013, 72, 127-138.	2.3	63
22	The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. Molecular Cancer Therapeutics, 2020, 19, 397-408.	4.1	18
23	HEPATOTOXICITY OF CHEMOTHERAPEUTIC AND ONCOLOGIC AGENTS. Gastroenterology Clinics of North America, 1995, 24, 969-990.	2.2	71
24	Treatment of Meningeal Malignancy. Oncologist, 1996, 1, 56-61.	3.7	6
25	Critical Illness as a Result of Anti-Neoplastic Therapy. , 2014, , 363-383.		0
26	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	3
27	Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor. Molecular Cancer Therapeutics, 2023, 22, 1390-1403.	4.1	0